The FDA’s July calendar includes at least 10 drug and biologics decision dates, including a cell therapy with an action date pushed back from April. Orca Therapeutics is among companies signaling readiness for regulatory outcomes linked to Orca-T, the allogeneic cell therapy approach in hematologic malignancies. The calendar preview also highlights how the agency’s scheduling continues to concentrate on high-impact therapeutic modalities, particularly those tied to advanced manufacturing and CMC readiness. For cell and gene therapy teams, calendar movements can directly affect launch timing, post-marketing planning, and investor read-through. Combined with the recent leadership change narrative, the July decisions underscore that regulatory execution remains a central driver of biotech near-term value.